**Scope**: What is the long-term adverse health and quality of life effects of the most commonly used breast cancer adjuvant chemotherapy regimens?

**Key Questions**

1. In women with early stage breast cancer, how does the use of adjuvant hormonal therapy affect long-term adverse health outcomes and how does it differ by age, race/ethnicity, and hormone receptor status?
2. In women with early stage breast cancer treated with adjuvant hormonal therapy, how does the effect on long-term adverse health outcomes differ by adjuvant hormonal therapy treatment type?
   1. What is the synergistic effect of the combination multiple adjuvant hormonal therapy types on long-term adverse health outcomes?
3. In with women with early stage breast cancer receiving adjuvant hormonal therapy, what is the impact of long-term health outcomes on patient quality of life?

**Other**

1. Among women with left-sided breast cancer, what is the impact of radiation on long-term adverse health outcomes?

**Research Approach**

|  |  |  |
| --- | --- | --- |
| **Category** | **Include** | **Exclude** |
| **Population** | Women of all ages with early stage (I-IIIA) breast cancer with any receptor status | Women with advanced stage (IIIB-IV) |
| **Intervention** | Adjuvant chemotherapy regimens (used alone or in combination)   * Anthracyclines   + Doxorubicin   + Epirubicin * Cyclophosphamide * Taxanes * Trastuzumab |  |
| **Comparisons** | Women with early stage breast cancer who did not receive adjuvant chemotherapy |  |
| **Outcomes:**  **Health** | Chemotherapy-related long-term adverse health outcomes   * Cardiac toxicity * Ovarian failure * Secondary malignancies * Neurotoxicity * Cognitive dysfunction |  |
| **Outcomes: Quality of Life** | Quality of life |  |
| **Timing** | Outcomes occurring or persisting beyond the first year of treatment |  |
| **Setting** |  |  |
| **Study Design** |  |  |
| **Language** |  |  |
| **Data Sources** |  |  |
| **Search Dates** |  |  |